Edition:
India

Taro Pharmaceutical Industries Ltd (TARO.N)

TARO.N on New York Stock Exchange

103.14USD
23 Aug 2017
Change (% chg)

$-0.33 (-0.32%)
Prev Close
$103.47
Open
$103.29
Day's High
$104.35
Day's Low
$102.79
Volume
10,404
Avg. Vol
18,811
52-wk High
$134.50
52-wk Low
$92.28

TARO.N

Chart for TARO.N

About

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical... (more)

Overall

Beta: 0.68
Market Cap(Mil.): $4,191.90
Shares Outstanding(Mil.): 40.51
Dividend: --
Yield (%): --

Financials

  TARO.N Industry Sector
P/E (TTM): 9.36 30.81 32.04
EPS (TTM): 11.05 -- --
ROI: 22.79 14.57 14.11
ROE: 22.84 15.66 15.43

Indian shrs fall for 3rd day; US-N.Korea tensions spook investors

Aug 9 Indian shares fell for a third consecutive session on Wednesday, dragged down by financial and healthcare stocks, as escalating tensions on the Korean peninsula hit regional markets.

09 Aug 2017

BUZZ-India's Sun Pharma falls to over 4-yr low

** Sun Pharmaceutical Industries' shares slump as much as 5 pct to lowest since June 2013

09 Aug 2017

BRIEF-Taro reports quarterly net income per ordinary share $1.35

* Qtrly net income per ordinary share $1.35 Source text for Eikon: Further company coverage:

09 Aug 2017

BUZZ-Taro Pharmaceutical: Shares down after Q4 revenue miss

** Generic drug maker's shares fall as much as 5.9 pct to $105.70; biggest intraday pct drop in more than 5 months

23 May 2017

BRIEF-Taro reports qtrly EPS $2.05

* Qtrly earnings per share $2.05 Source text for Eikon: Further company coverage:

23 May 2017

BRIEF-Crescita Therapeutics announces agreement with Taro Pharmaceuticals for Pliaglis

* Crescita Therapeutics announces agreement with Taro Pharmaceuticals for Pliaglis

25 Apr 2017

BRIEF-Bellus Health to sell subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals

* Press release - Bellus Health announces the sale of subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals

17 Mar 2017

Earnings vs. Estimates